These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 15079155)

  • 1. Treatment of hematological malignancies with allogeneic nonmyeloablative stem cell transplantation: conditioning regimens with fludarabine.
    Carella AM
    Hematol J; 2004; 5 Suppl 1():S68-75. PubMed ID: 15079155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Baron F; Beguin Y
    J Hematother Stem Cell Res; 2002 Apr; 11(2):243-63. PubMed ID: 11983097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Georges GE; Storb R
    Int J Hematol; 2003 Jan; 77(1):3-14. PubMed ID: 12568294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning.
    Kim I; Lee KH; Choi Y; Keam B; Koo NH; Yoon SS; Yoo KY; Park S; Kim BK
    J Korean Med Sci; 2007 Apr; 22(2):227-34. PubMed ID: 17449929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-myeloablative transplants for malignant disease.
    Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
    Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
    Petersen EJ; Lokhorst HL; Verdonck LF
    Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.
    Fung HC; Cohen S; Rodriguez R; Smith D; Krishnan A; Somlo G; Sahebi F; Senitzer D; O'Donnell MR; Stein A; Snyder DS; Spielberger R; Bhatia R; Falk P; Molina A; Nademanee A; Parker P; Kogut N; Popplewell L; Vora N; Margolin K; Forman SJ
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):649-56. PubMed ID: 14569561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
    Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.
    Morecki S; Gelfand Y; Nagler A; Or R; Naparstek E; Varadi G; Engelhard D; Akerstein A; Slavin S
    Bone Marrow Transplant; 2001 Aug; 28(3):243-9. PubMed ID: 11535991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience.
    Shimoni A; Nagler A
    Curr Hematol Rep; 2004 Jul; 3(4):242-8. PubMed ID: 15217553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
    Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges.
    Satwani P; Harrison L; Morris E; Del Toro G; Cairo MS
    Biol Blood Marrow Transplant; 2005 Jun; 11(6):403-22. PubMed ID: 15931629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minitransplants: allogeneic stem cell transplantation with reduced toxicity.
    Beguin Y; Baron F
    Acta Clin Belg; 2003; 58(1):37-45. PubMed ID: 12723260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation.
    Picardi A; Fabritiis Pd Pd; Cudillo L; Dentamaro T; Cupelli L; Ballatore G; Venditti A; Caravita T; Cristina Cox M; Catalano G; Amadori S
    Hematol J; 2004; 5(1):24-31. PubMed ID: 14745426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.